Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa

Medical Hypotheses

Volumn 54, Issue 5, 2000, Pages 814-824

  Baumgartner, W A ^a  

^a Ianus Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CYTOCHROME C; FREE RADICAL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; METHAMPHETAMINE; NORSELEGILINE; OZONE; PROTEIN BAX; PROTEIN BCL 2; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CHEMICAL REACTION; CHINESE MEDICINE; DIET SUPPLEMENTATION; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERBARIC OXYGEN; MITOCHONDRION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA CONE; RETINA ROD; RETINITIS PIGMENTOSA; REVIEW; STRESS; TRANSGENIC MOUSE; VISUAL FIELD;

ANIMALIA; MUS MUSCULUS;

EID: 0034087064     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0957     Document Type: Article

References (46)

1. Massof R. W., Dagnelia G., Benzschawel T., Palmer R. W., Finkelstein D. First order dynamics of visual field loss in retinitis pigmentosa. Clin Vision Sci. 5:1990;1-26.
2. Jules Stein Eye Institute pamphlet. 1992.
3. Information pamphlet of RP Foundation Fighting Blindness. 1986.
4. Berson E. L., Sandberg M. A., Rosner B., Birch D. G., Houson A. H. Natural course of retinitis pigmentosa over a three year interval. Am J Ophthalmol. 919:1985;24-251.
5. Adler R. Mechanisms of photoreceptor death in retinal degeneration: from the cell biology of the 1990s to the ophthalmology of the 21st century. Arch Ophthalmol. 141:1996;79-83.
6. Nickles R. W., Zack D. J. Apoptosis in ocular disease: a molecular overview. Ophthalmic Genetics. 17:1996;145-165.
7. Tatton, W. G. Olanow, C. W. Apoptosis in neurodegenerative disease: the role of mitochondria. Biochim Biophys Acta.
8. Tatton W. G., Ju W., Wadia J. (-)-Deprenyl reduces neuronal apoptosis by maintaining Bcl-2 synthesis and mitochondrial membrane potential. Mov Disord. 9:1994;4.
9. Tatton W. G., Wu W. Y., Holland D. P., Tai C., Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem. 63:1994;1572-1575.
10. Tatton W. G., Ju W. J. H., Wadia J., Tatton N. A. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. Olanow C. W., Jenner P., Youdim M. Neurodegeneration and and neuroprotection in Parkinson's disease. 1996;209-229 Academic Press, London.
11. Tatton W. G., Chalmers-Redman R. M. E. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 47:1996;S171-183.
12. Olanow, C. W. Tatton, W. G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci.
13. Peng L., Nijjhawan D., Budihardya I. Cytochrome c and d-ATP-dependent Apaf-1/caspase-9 complex initiate an apoptotic protease cascade. Cell. 91:1997;479-489.
14. Susin S. A., Zamzami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta. 1366:1998;151-165.
15. Hagan T. M., Yowe D. L., Bartholomew J. C. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci USA. 94:1997;3069-3084.
16. Chen J., Flannery J. G., Vail M. M., Steinberg R. H., Xu J., Simon M. I. Bcl-2 overexpression reduces apoptotic photoceptor cell death in three different retinal degenerations. Proc Natl Acad Sci USA (Cell Biology). 93:1996;7042-7047.
17. Wong F. Investigating retinitis pigmentosa: a laboratory scientist's perspective. Progress in Retinal Eye Research. 16:1997;353-373.
18. Newell, F. W. Ophthalmology: Principles and concepts. New York, Mosby, 1992, 304, 305.
19. Murphy M. F., Sramek J. J., Kurtz N. M., Carta A., Cutler N. R. Alzheimers Disease. London: Greenwich Medical Media, 1998;82-83.
20. Newsome D. A., Micele M. V., Liles M. R., Tate D. J., Oliver P. D. Antioxidants in the retinal pigment epithelium. Progress in Retinal and Eye Research. 13:1994;101-122.
21. Voaden M. J. Retinitis pigmentosa and its models. Progress in Retinal and Eye Research. 10:1991;293-331.
22. Organisciak D. T., Winkler B. S. Retinal light damage: practical and theoretical considerations. Progress in Retinal and Eye Research. 13:1994;1-29.
23. Organisciak, D. T. Xie, A. Reeves, D. S. Donosa, L. A. Intense light mediates changes in rat rod outer segment lipids and proteins. Inherited and environmentally induced retinal degenerations. Alan R. Liss Inc. 1989, 493, 512.
24. Moses, R. A. Adler's Physiology of the Eye. 1981, 415.
25. Young, R. W. Solar radiation and age-related macular degeneration. Surv Ophthalmol, 32, 252, 269.
26. Pautler E. L., Morita M., Beezley D. Hemoprotein(s) mediated blue-light damage in the retinal pigment epithelium. Photochem Photobiol. 51:1990;599-605.
27. Shedova A. A., Alekseeva O. M., Kuliev I. Y., Muranov K. O., Kozlov Y. P., Kagan V. E. Damage of photoreceptor membrane lipids and proteins induced by photosensitized generation of singlet oxygen. Curr Eye Res. 2:1983;683-689.
28. Delmelle M. Possible implication of photooxidation reactions in retinal photodamage. Photochem Photobiol. 29:1979;173-716.
29. Noell W. A. Possible mechanisms of photoreceptor damage by light in mammalian eyes. Vision Research. 20:1980;1163-1171.
30. Richter S. R., Sardi R. P. The search for a new paradigm. Focus. 1:1997;1-45.
31. Schwarz, K. Baumgartner, W. A. Kinetic studies of mitochondrial enzymes during respiratory decline relating to the mode of action of tocopherol. Harry Steenbock Symposium on Fat Soluble Vitamins in The Fat Soluble Vitamins, 1969, DeLuca, H. F.Suttie, J. W. University of Wisconsin Press, 317, 346.
32. Baumgartner W. A., Hill V. A., Wright E. T. Anomalous vitamin E effects on acetaldehyde and mitochondrial oxidative metabolism. Mech Aging Dev. 8:1978;311-328.
33. Chance B., Sies H., Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 59:1979;527-589.
34. Berson E. L. Retinitis pigmentosa: unfolding its mystery. Proc Natl Acad Sci USA. 93:1996;4526-4528.
35. Berson E. L., Rosner B., Sandberg M. A. A randomized trial of vitamin A and vitamin E supplements for retinitis pigmentosa. Arch Ophthalmol. 111:1993;761-772.
36. Rose, M. Rose, M. R. Save Your Sight. Time Warner Company, 1998.
37. Strehler, B. L. Time, Cells, and Aging. Academic Press, 1962, 86, 111.
38. Knoll J. The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)-deprenyl. Mech Aging Dev. 46:1988;237-262.
39. Dow, A. Deprenyl, the anti-aging drug. Canada, Hallberg Publishing Company, 1990.
40. Snyder S. H., Sabatini D. M., Lai M. M., Steiner J. P., Hamilton G. S., Suzdatz P. D. Neural actions of immunophilin ligands. TIPS. 19:1998;21-26.
41. Gold, B. G. FK506 and the role of immunophilins in nerve regenerations. Mol Neurobiol, 15, 285, 306.
42. Davydova G. A., Mukha A. I. Vasoactive agent picamilon in pigmented retinal dystrophy. Russian Federation Vestnik Oftalmologii. 111:1995;20-22.
43. Vingolo E. M., Pelaia P., Giusti C., Forte R., Rocco M., Pannarale M. R. Retinitis pigmentosa and hyperbaric oxygen therapy: three year follow-up. Invest Ophthal Vis Sci. 37:1996;#487-B399.
44. Katznelson L. A., Khoroshilova-Maslova I. P., Eliseyeva R. F. A new method of treatment of retinitis pigmentosa/pigmentary abiotrophy. Ann Ophthalmol. 22:1990;167-172.
45. Personal Communication, Tatton W.
46. Kragten E., Lalande I., Zimmermann K. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP3466 and R-(-)-deprenyl. J Biol Chem. 10:1998;5821-5828.